Cargando…

Identification of Isocitrate Dehydrogenase 2 (IDH2) Mutation in Carotid Body Paraganglioma

Carotid body paragangliomas (PGLs) are rare neuroendocrine tumors that develop within the adventitia of the medial aspect of the carotid bifurcation. Carotid body PGLs comprise about 65% of head and neck paragangliomas, however, their genetic background remains elusive. In the present study, we repo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lang, Fengchao, Jha, Abhishek, Meuter, Leah, Pacak, Karel, Yang, Chunzhang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488436/ https://www.ncbi.nlm.nih.gov/pubmed/34616365 http://dx.doi.org/10.3389/fendo.2021.731096

Ejemplares similares

Reactive Oxygen Species: A Promising Therapeutic Target for SDHx-Mutated Pheochromocytoma and Paraganglioma
por: Hadrava Vanova, Katerina, et al.
Publicado: (2021)

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
por: Liu, Yang, et al.
Publicado: (2020)

Pediatric Metastatic Pheochromocytoma and Paraganglioma: Clinical Presentation and Diagnosis, Genetics, and Therapeutic Approaches
por: Kuo, Mickey J. M., et al.
Publicado: (2022)

Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World
por: Patel, Mayank, et al.
Publicado: (2021)

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
por: Murugan, A. K., et al.
Publicado: (2022)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
por: Su, Li, et al.
Publicado: (2020)

Metabolome-guided genomics to identify mutations in isocitrate dehydrogenase, fumarate hydratase and succinate dehydrogenase genes in pheochromocytoma and paraganglioma
por: Richter, Susan, et al.
Publicado: (2018)

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
por: Chen, Jun-Rui, et al.
Publicado: (2016)

Early short-term effects on catecholamine levels and pituitary function in patients with pheochromocytoma or paraganglioma treated with [(177)Lu]Lu-DOTA-TATE therapy
por: Gubbi, Sriram, et al.
Publicado: (2023)

Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas
por: Neumaier, Felix, et al.
Publicado: (2023)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation
por: KAWAKAMI, Shota, et al.
Publicado: (2017)

Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies
por: Pang, Ying, et al.
Publicado: (2019)

SUN-330 Non-Mosaic Somatic HIF2A Mutations Associated with Late-Onset Polycythemia-Paraganglioma Syndrome: Newly Recognized Subclass of Polycythemia-Paraganglioma Syndrome
por: Pang, Ying, et al.
Publicado: (2019)

Somatic mosaicism of EPAS1 mutations in the syndrome of paraganglioma and somatostatinoma associated with polycythemia
por: Yang, Chunzhang, et al.
Publicado: (2015)

Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma
por: Gubbi, Sriram, et al.
Publicado: (2021)

An Analysis of the Prognostic Value of IDH1 (Isocitrate Dehydrogenase 1) Mutation in Polish Glioma Patients
por: Lewandowska, Marzena Anna, et al.
Publicado: (2013)

Radiological Prediction of Isocitrate Dehydrogenase (IDH) Mutational Status and Pathological Verification for Lower-Grade Astrocytomas
por: Yano, Hirohito, et al.
Publicado: (2022)

PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma
por: Hadrava Vanova, Katerina, et al.
Publicado: (2022)

Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities
por: Garrett, Matthew, et al.
Publicado: (2018)

Expression of CD133 Cancer Stem Cell Marker in IDH-Mutant and IDH-wildtype (Isocitrate Dehydrogenase) Astrocytoma
por: Sabunga, Olivia Desty, et al.
Publicado: (2022)

Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCR(TM) In Patients With AML And Their Clinical Impact In Mexico City
por: Olarte, Irma, et al.
Publicado: (2019)

Targeting NRF2-Governed Glutathione Synthesis for SDHB-Mutated Pheochromocytoma and Paraganglioma
por: Liu, Yang, et al.
Publicado: (2020)

Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma
por: Ilanchezhian, Maran, et al.
Publicado: (2020)

Isocitrate protects DJ-1 null dopaminergic cells from oxidative stress through NADP(+)-dependent isocitrate dehydrogenase (IDH)
por: Yang, Jinsung, et al.
Publicado: (2017)

Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning
por: Liu, Sidong, et al.
Publicado: (2020)

Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients
por: Chotirat, Sadudee, et al.
Publicado: (2012)

Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas
por: Amary, M. Fernanda, et al.
Publicado: (2014)

PSUN27 Largest Cohort of Cervical Spine Metastases of Pheochromocytoma/Paraganglioma in the Setting of SDHB Mutation
por: Pacak, Karel, et al.
Publicado: (2022)

Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas
por: Matlac, Dieter M., et al.
Publicado: (2021)

Crystal Structure of the Isocitrate Dehydrogenase 2 from Acinetobacter baumannii (AbIDH2) Reveals a Novel Dimeric Structure with Two Monomeric-IDH-Like Subunits
por: Wang, Peng, et al.
Publicado: (2018)

SIRT3 and GCN5L regulation of NADP+- and NADPH-driven reactions of mitochondrial isocitrate dehydrogenase IDH2
por: Smolková, Katarína, et al.
Publicado: (2020)

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
por: Wang, Zheng, et al.
Publicado: (2013)

Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia
por: Willander, Kerstin, et al.
Publicado: (2014)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

Carotid body paraganglioma
por: Pitchaiprasert, Suwanna, et al.
Publicado: (2019)

Carotid Body Paraganglioma
por: Hosalkar, Rashmi Maruti, et al.
Publicado: (2019)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma
por: Dubinski, Daniel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_buo6p1dpj8032pbqij7jgphn7t